Document 0447
 DOCN  M9550447
 TI    Correlation of antiphospholipid antibodies and protein S deficiency with
       thrombosis in HIV-infected men.
 DT    9505
 AU    Hassell KL; Kressin DC; Neumann A; Ellison R; Marlar RA; Department of
       Medicine, Denver VA Medical Center, CO 80220.
 SO    Blood Coagul Fibrinolysis. 1994 Aug;5(4):455-62. Unique Identifier :
       AIDSLINE MED/95143382
 AB    Antiphospholipid antibodies (aPL) and free protein S (PSF) deficiency
       have been associated with clinical thrombosis. Previous reports
       described a high prevalence of these abnormalities in HIV-infected
       individuals, but suggested there was little associated clinical
       thrombosis. A cohort of 74 HIV-infected men were studied for aPL, PSF
       deficiency and the development of thrombosis. aPL, predominantly
       anticardiolipin antibodies (aCL), were detected in 86% and PSF
       deficiency in 33%. While 42% of men with aPL also had low PSF levels,
       there was no correlation between aCL titres or most measures of aPL and
       PSF levels. However, a strong correlation was noted between a subset of
       aPL that reacted to phosphatidylethanolamine by hexagonal array assay
       and low PSF levels. There was no significant correlation between aPL,
       PSF deficiency and clinical features (medication use, opportunistic
       infection, CD4 cell count) of HIV in 60 patients for whom clinical
       information was available. The overall incidence of thrombosis in this
       group was 18%, and thrombosis developed in 6.6% of those followed
       prospectively over a median follow-up of 12 months. Development of
       thrombosis was not significantly correlated with aPL or PSF deficiency,
       but the high prevalence of these abnormalities may necessitate larger
       study groups to determine the risk associated with these coagulation
       changes. Study of a larger group with careful analysis of subsets of
       aPL, especially those associated with low PSF levels, and longer
       clinical follow-up could identify the HIV-infected individuals at risk
       for thrombosis.
 DE    Adult  Antibodies, Anticardiolipin/BLOOD  Antibodies,
       Antiphospholipid/*BLOOD  Carrier Proteins/ANALYSIS  Cohort Studies
       Follow-Up Studies  Glycoproteins/ANALYSIS  Human  HIV
       Infections/BLOOD/*COMPLICATIONS  Incidence  Lupus Coagulation
       Inhibitor/ANALYSIS  Male  Middle Age  Prevalence  Prospective Studies
       Protein S Deficiency/BLOOD/*COMPLICATIONS/EPIDEMIOLOGY  Retrospective
       Studies  Thrombosis/EPIDEMIOLOGY/*ETIOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).